Limits...
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus

The dynamic conformational changes of the PDE5 showing active and inactive form. For full details see text. The structure of the PDE5 as explained in Figure 5. The red dots represent cGMP and black dots represent PDE5 inhibitor.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4352681&req=5

fig7: The dynamic conformational changes of the PDE5 showing active and inactive form. For full details see text. The structure of the PDE5 as explained in Figure 5. The red dots represent cGMP and black dots represent PDE5 inhibitor.

Mentions: In the last decade, much has been discovered about the dynamic of the PDE5 enzyme. The PDE5 holoenzyme can be present in inactive and active forms associated with conformational changes which are important in the PDE5 function.34 These changes undergo both positive and negative regulatory feedback (Figure 7).


The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Butrous G - Glob Cardiol Sci Pract (2014)

The dynamic conformational changes of the PDE5 showing active and inactive form. For full details see text. The structure of the PDE5 as explained in Figure 5. The red dots represent cGMP and black dots represent PDE5 inhibitor.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4352681&req=5

fig7: The dynamic conformational changes of the PDE5 showing active and inactive form. For full details see text. The structure of the PDE5 as explained in Figure 5. The red dots represent cGMP and black dots represent PDE5 inhibitor.
Mentions: In the last decade, much has been discovered about the dynamic of the PDE5 enzyme. The PDE5 holoenzyme can be present in inactive and active forms associated with conformational changes which are important in the PDE5 function.34 These changes undergo both positive and negative regulatory feedback (Figure 7).

Bottom Line: Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions.In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

View Article: PubMed Central - PubMed

ABSTRACT
Phosphodiesterase inhibitors (PDE) can be used as therapeutic agents for various diseases such as dementia, depression, schizophrenia and erectile dysfunction in men, as well as congestive heart failure, chronic obstructive pulmonary disease, rheumatoid arthritis, other inflammatory diseases, diabetes and various other conditions. In this review we will concentrate on one type of PDE, mainly PDE5 and its role in pulmonary vascular diseases.

No MeSH data available.


Related in: MedlinePlus